Education
About Us
Working with TipRanks
Follow Us
Sipai Health Technology Co., Ltd. (HK:0314)
:0314
0314 Stock Chart & Stats
HK$2.48
HK$0.09(1.75%)
At close: 4:00 PM EST
HK$2.48
HK$0.09(1.75%)
Day’s Range― - ―
52-Week RangeHK$2.05 - HK$7.38
Previous CloseN/A
Volume1.18M
Average Volume (3M)2.05M
Market Cap
HK$1.73B
Enterprise ValueHK$1.25B
Total Cash (Recent Filing)HK$597.85M
Total Debt (Recent Filing)HK$24.70M
Price to Earnings (P/E)―
Beta0.31
Next Earnings
Mar 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.13
Shares Outstanding765,578,100
10 Day Avg. Volume1,436,880
30 Day Avg. Volume2,048,921
Financial Highlights & Ratios
PEG Ratio-0.37
Price to Book (P/B)2.67
Price to Sales (P/S)0.72
P/FCF Ratio-48.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Business Model & Product FocusSipai's core focus on diagnostic tools and health monitoring for clinical and personal use establishes a durable product-led business model. Serving both clinical and consumer markets supports multiple adoption paths, helping sustained revenue potential as healthcare digitizes and chronic care management grows.
Balance Sheet ImprovementRelatively low leverage and a move to positive equity materially reduce refinancing and solvency risk over the next several quarters. This stronger capital structure supports continued R&D and commercialization investment without immediate pressure from creditors, improving strategic optionality.
Diversified Revenue ChannelsMultiple sales channels—hospitals, providers, retail—plus partnerships, licensing and possible subscription models lower concentration risk and enhance resilience. Diversification supports more stable cash inflows and creates options to scale recurring revenue over time as solutions embed into care workflows.
Bears Say
Persistent UnprofitabilitySustained negative profitability erodes retained earnings and limits ability to self-fund growth or absorb shocks. Prolonged negative margins indicate structural cost or pricing issues that, unless resolved, will continue to impair ROE and constrain long-term reinvestment into products and market expansion.
Negative Operating And Free Cash FlowPersistent negative operating and free cash flow forces reliance on external financing, raising dilution or interest burden risk. Weak cash conversion limits the firm’s ability to scale commercial operations, invest in R&D or weather downturns, making long-term execution more fragile.
Declining Revenue TrendA steep revenue decline indicates weakening demand or competitive pressures that reduce scale benefits and pressure margins. Without a credible revenue stabilization plan, lower top-line trends will hamper recovery of profitability and cash flow, increasing strategic and operational risk over months.
Sipai Health Technology Co., Ltd. News
0314 FAQ
What was Sipai Health Technology Co., Ltd.’s price range in the past 12 months?
Sipai Health Technology Co., Ltd. lowest stock price was HK$2.05 and its highest was HK$7.38 in the past 12 months.
What is Sipai Health Technology Co., Ltd.’s market cap?
Sipai Health Technology Co., Ltd.’s market cap is HK$1.73B.
When is Sipai Health Technology Co., Ltd.’s upcoming earnings report date?
Sipai Health Technology Co., Ltd.’s upcoming earnings report date is Mar 24, 2026 which is in 26 days.
How were Sipai Health Technology Co., Ltd.’s earnings last quarter?
Sipai Health Technology Co., Ltd. released its earnings results on Aug 18, 2025. The company reported -HK$0.131 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.131.
Is Sipai Health Technology Co., Ltd. overvalued?
According to Wall Street analysts Sipai Health Technology Co., Ltd.’s price is currently Overvalued.
Does Sipai Health Technology Co., Ltd. pay dividends?
Sipai Health Technology Co., Ltd. does not currently pay dividends.
What is Sipai Health Technology Co., Ltd.’s EPS estimate?
Sipai Health Technology Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sipai Health Technology Co., Ltd. have?
Sipai Health Technology Co., Ltd. has 765,578,100 shares outstanding.
What happened to Sipai Health Technology Co., Ltd.’s price movement after its last earnings report?
Sipai Health Technology Co., Ltd. reported an EPS of -HK$0.131 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.864%.
Which hedge fund is a major shareholder of Sipai Health Technology Co., Ltd.?
Currently, no hedge funds are holding shares in HK:0314
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sipai Health Technology Co., Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-47.42%
12-Months-Change
Fundamentals
Return on Equity
-25.47%
Trailing 12-Months
Asset Growth
-35.95%
Trailing 12-Months
Company Description
Sipai Health Technology Co., Ltd.
Sipai Health Technology Co., Ltd. operates as a medical technology and health management company in the People's Republic of China. The company operates through three segments: Specialty Pharmacy Business, Physician Research Assistance Business, and Health Insurance Services Business. The Specialty Pharmacy Business segment operates specialty pharmacy stores; and distributes pharmaceutical products to pharmaceutical companies and other distributors. The Physician Research Assistance Business segment offers pharmaceutical companies and other clinical trial institutions site management organization services, including site feasibility, site initiation, patient recruitment, patient management, data entry and document management, on-site drug management and bio-sample management, site closure, and others; and services for image management in clinical trials. The Health Insurance Services Business segment provides insurance brokerage services to insurance companies. The company was founded in 2014 and is headquartered in Guangzhou, the People's Republic of China.
Technical Analysis
Peijia Medical Ltd.
―
Shanghai Kindly Medical Instruments Co., Ltd. Class H
―
China Isotope & Radiation Corp.
―
IVD Medical Holding Limited
―
Jiangsu Recbio Technology Co., Ltd. Class H
―
Options Prices
Currently, No data available
---